Conferences - Results from #240

Viewing 241-260 of 11300 articles

EAU 2024: Moving Towards Intensified Treatment Paradigms in First Line Metastatic Kidney Cancer: Triplet Combinations at Any Cost - Is More Always Better? Yes, the More the Merrier

EAU 2024: TiP: Phase 3 Study of Disitamab Vedotin with Pembrolizumab Versus Chemotherapy in Patients with Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma That Expresses HER2 (DV-001)

EAU 2024: Moving Towards Intensified Treatment Paradigms in First Line Metastatic Kidney Cancer: Triplet Combinations at Any Cost - Is More Always Better? No, Less Is More

EAU 2024: Negative Staging PSMA in High-Risk Disease: Can We Skip Extended Pelvic Lymph Node Dissection? Yes, We Can

EAU 2024: Pembrolizumab in BCG Refractory Non-Muscle Invasive Bladder Cancer is Associated with High Rates of Adverse Events and Discontinuation of Treatment

EAU 2024: State-of-the-Art Lecture: Clinical and Molecular Stratification of Men with Biochemical Recurrence After Radical Prostatectomy

EAU 2024: Negative Staging PSMA in High-Risk Disease: Can We Skip Extended Pelvic Lymph Node Dissection? No, We Cannot

EAU 2024: Pelvic Lymph Node Dissection in Prostate Cancer: Update of the Limited vs. Extended Randomized Clinical Trial

EAU 2024: State-of-the-Art Lecture: How to Personalize Treatment in mHSPC? More than Just Counting Metastases

EAU 2024: State-of-the-Art Lecture: New Standard Treatment for Metastatic Bladder Cancer Based on EV-302/KEYNOTE-A39?

EAU 2024: Synchronous mHSPC: What Are the Treatment Options and What Are the Goals of Treatment? Germline Genetic Testing Necessary And/or Helpful?

EAU 2024: Synchronous mHSPC: What are the Treatment Options and What Are the Goals of Treatment? What Is the Evidence for Surgery?

EAU 2024: Synchronous mHSPC: What Are the Treatment Options and What Are the Goals of Treatment? What Is the Evidence for Systemic Therapy in Synchronous Low-Volume mHSPC

EAU 2024: Living with a Prostate Cancer Patient: Real-World Evidence from the Unprecedented Europa Uomo Prostate Cancer Partners in Europe Research (EU-ProPER) Study

EAU 2024: Does Scalpel Play a Role in Intermediate Risk Metastatic RCC? dCN

EAU 2024: Adjuvant Immunotherapy After pT3a F IV /N0 at Nephrectomy: Is That Real High-Risk for All? No

EAU 2024: Does Scalpel Play a Role in Intermediate Risk Metastatic RCC? Upfront CN

EAU 2024: State-of-the-Art Lecture: Staging High-Risk Prostate Cancer with PSMA PET: Strengths and Pitfalls

EAU 2024: Efficacy of Transrectal and Transperineal Prostate Biopsy in Detecting Clinically Significant Prostate Cancer: Results of the ProBE-PC Randomised Clinical Trial

EAU 2024: Risk Adapted Screening for Prostate Cancer in Europe: PSA + MRI + Targeted Biopsies Only (Gothenburg-2 Trial)

8
9
10
11
12
13
14
15
16
17